Gland Pharma Limited has intimated the stock exchanges about an upcoming Board of Directors meeting scheduled for Friday, November 06, 2026. The primary agenda of the meeting is to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.
The trading window for dealing in the company's securities has been closed since Thursday, October 01, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended. The trading window will reopen on Monday, November 09, 2026.
An Investor/Analyst earnings call is scheduled for Friday, November 06, 2026, at 18:30 Hrs (IST). Further details regarding the earnings call will be communicated to the stock exchanges and published on the company's website (www.glandpharma.com) in due course.
The disclosure is made under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication is signed by Pallerlamudi Sampath Kumar, Company Secretary & Compliance Officer of Gland Pharma Limited.